At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
risankizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (1311.5)
In Brief
A Phase 2 clinical trial evaluating risankizumab for Psoriatic Arthritis. Completed, enrolled 145 participants.
Detailed Summary
This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in participants with psoriatic arthritis (PsA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionJul 2018
Study CompletionJul 2018
TodayJul 2026
First PostedDec 8, 2016
Enrollment StartDec 15, 2016
Primary CompletionJul 8, 2018
Study CompletionJul 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.6 years ago
Interventions
risankizumabbiological
Risankizumab administered by subcutaneous injection.